| Lasofoxifene - Wikipedia, the free encyclopedia Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention ... Read More |
| Lasofoxifene.com - The official site for lasofoxifene information The reference site for lasofoxifene including news articles, images, and updated information Read More |
| Latest news articles regarding Lasofoxifene The latest news, research and development and press releases related to lasofoxifene and its brand equivalents Read More |
| Fablyn (Lasofoxifene) - Investigational SERM - Drug Development ... The product of a joint development programme between Pfizer and Ligand Pharmaceuticals, Fablyn, formerly Oporia (lasofoxifene) is a selective oestrogen receptor ... Read More |
| Oporia (lasofoxifene) for osteoporosis : FDA judges lasofoxifene "nonapprovable" for osteoporosis. ... Instant Lookup Access over 10,000 topics by title ...or, search within full reference content Read More |
| Pfizer Receives FDA Complete Response Letter For Lasofoxifene Pfizer Inc said it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company's ... Read More |
| Osteoporosis Drug May Fight Several Diseases The osteoporosis drug lasofoxifene may help postmenopausal women reduce their risk of broken bones as well as fight breast cancer, heart disease, and ... Read More |
| Lasofoxifene: Evidence of its therapeutic value in osteoporosis Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte 53100-Siena, Italy Read More |
| Susan G. Komen for the Cure | Lasofoxifene Promising for Breast ... Lasofoxifene, a selective estrogen receptor modulator (SERM), appears to reduce the risk of breast cancer among postmenopausal women with osteoporosis. Read More |
| Lasofoxifene Is Potential New Option for Breast Cancer Risk ... Lasofoxifene Is Potential New Option for Breast Cancer Risk Reduction. Adapted from the NCI Cancer Bulletin. An investigational agent in the same family of drugs as ... Read More |
